Showing results (241-250 of 293) with videos related to
Sort By:
Pageof 30
Journal of Immunology (Baltimore, Md. : 1950)|April 28, 2022
Carbon Dioxide Sensing by Immune Cells Occurs through Carbonic Anhydrase 2-Dependent Changes in Intracellular pHMoritz J Strowitzki, Ross Nelson, Mario P Garcia, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 1, 2019
Hydroxylase Inhibition Selectively Induces Cell Death in MonocytesBianca Crifo, Bettina Schaible, Eric Brown, et al.Cancer Chemotherapy and Pharmacology|November 30, 2011
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumorsGopa Iyer, Michael J Morris, Dana Rathkopf, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.Frontiers in Oncology|June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian CancerJung-Min Lee, Jane B Trepel, Peter Choyke, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancersRamesh K Ramanathan, Donald L Trump, Julie L Eiseman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeChanning J Paller, Penelope A Bradbury, S Percy Ivy, et al.Gynecologic Oncology|March 15, 2015
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortiaIvan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium studyRochelle Bagatell, Lia Gore, Merrill J Egorin, et al.Cancer Chemotherapy and Pharmacology|April 17, 2008
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabineSmitha S Krishnamurthi, Joanna M Brell, Charles L Hoppel, et al.Pageof 30